Neil Averitt commentary: Amgen-Horizon case raises possibility of personalized merger law

Washington, D.C. (June 6, 2023) -- At first glance, the Federal Trade Commission’s complaint targeting the Amgen-Horizon deal seems ill-conceived and overbroad, but on second look there may be a hidden logic behind it. The history of the two companies could also become a factor in the analysis....

Related Sections